重药控股分析师会议 调研日期：2025年09月04日 调研行业：医药商业 参与调研的机构：中信证券等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 ...

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the Shanghai First Pharmaceutical Co., Ltd. 2025 Second Extraordinary General Meeting of Shareholders held on September 4, 2025 [1][6]. Group 1: Meeting Summons - The company announced the convening of the 2025 Second Extraordinary General Meeting of Shareholders on August 20, 2025, via the Shanghai Stock Exchange website [3]. - The meeting was scheduled to take place on September 4, 2025, with all necessary details communicated to shareholders 15 days prior [3]. Group 2: Meeting Proceedings - The meeting was held at the designated location, and the voting time was set for the trading hours of September 4, 2025, from 9:15 to 9:25 [3][4]. - Specific voting procedures for margin trading and other related accounts were outlined in accordance with regulatory guidelines [3]. Group 3: Attendance and Voting - A total of 2 shareholders and their representatives attended the meeting, representing 100,854,234 shares with voting rights, which accounted for a significant portion of the total voting shares [4]. - Additionally, 141 shareholders participated in the voting through an online system, with their qualifications verified by the system provider [5]. Group 4: Proposals and Voting Results - The meeting included proposals such as the reappointment of the internal control auditing accounting firm, which were approved by a majority of the voting rights present [5]. - The voting results were announced, confirming that all resolutions passed were in compliance with relevant laws and regulations [5][6]. Group 5: Conclusion - The legal opinion concludes that all aspects of the meeting, including the summons, proceedings, attendance, proposals, and voting, adhered to the applicable laws and the company's articles of association, rendering the resolutions valid [6].

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.07% on September 4, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the pharmaceutical commercial sector included: - HeFu China (603122) with a closing price of 6.66, up 1.99% [1] - JianZhiJia (605266) at 21.56, up 1.84% [1] - YiXinTang (002727) at 14.98, up 1.70% [1] - Saily Medical (603716) was the biggest loser, closing at 29.00, down 2.26% [2] Trading Volume and Value - The trading volume and value for selected stocks were as follows: - YiXinTang (002727) had a trading volume of 144,800 hands and a transaction value of 216 million [1] - Saily Medical (603716) recorded a trading volume of 256,800 hands with a transaction value of 759 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 169 million from institutional investors, while retail investors had a net inflow of 210 million [2] - Key stocks with significant capital flow included: - BaiYang Pharmaceutical (301015) with a net inflow of 15.09 million from institutional investors [3] - LaoBaiXing (603883) with a net inflow of 13.41 million from institutional investors [3]

Group 1: Financial Performance - The company's operating revenue for the first half of 2025 reached 41.188 billion yuan, representing a year-on-year growth of 3.54% [2] - The net profit attributable to shareholders was 2.82 billion yuan, with a year-on-year increase of 18.56% [2] - The net profit excluding non-recurring items was 2.77 billion yuan, showing a year-on-year growth of 26.68% [2] Group 2: Third-party Storage and Distribution Business - The revenue from the third-party storage and distribution business exceeded 15 million yuan during the reporting period, expanding into various fields including traditional Chinese medicine, e-commerce, medical devices, and radiopharmaceuticals [2] Group 3: Narcotic and Psychotropic Drugs - The sales of narcotic and psychotropic drugs amounted to 1.736 billion yuan, reflecting a year-on-year increase of 19.07% [3] - The company is one of three national wholesale enterprises for narcotic drugs, with a sales network covering all 31 provinces and regions [3] Group 4: Financial Cost Management - Financial costs decreased significantly, with a reduction of 165 million yuan, marking a year-on-year decline of 30.35% [3] - The financial cost rate reached a five-year low, with expectations for further reductions in the future [3] Group 5: Collaboration with General Technology Group - The company accelerated collaboration with medical institutions under the General Technology Group, opening 104 accounts in 22 provinces, including 89 grade hospitals [3] - A strategic cooperation agreement was signed with General Health and China Pharmaceutical to enhance resource integration and optimize supply chain management [3]

Investment Rating - The report has downgraded the investment rating for the pharmaceutical and biotechnology industry, indicating that most sub-sectors are under performance pressure and suggesting a focus on performance improvement directions [1]. Core Insights - The overall revenue and net profit attributable to the parent company in the pharmaceutical and biotechnology industry saw a decline in H1 2025, with total revenue of 1.23 trillion yuan, down 2.7% year-on-year, and net profit of 99.15 billion yuan, down 3.9% year-on-year [4][13]. - Most sub-sectors experienced a year-on-year decline in performance in H1 2025, with only a few segments like medical R&D outsourcing and other biological products showing positive growth [4][14]. - The investment strategy suggests focusing on innovative drugs and medical devices, highlighting companies such as Heng Rui Medicine, Bei Da Pharmaceutical, and Mindray Medical as potential investment opportunities [4]. Summary by Sections Overall Industry Performance - In H1 2025, the pharmaceutical and biotechnology industry reported total revenue of 1.23 trillion yuan, a decrease of 2.7% year-on-year, and a net profit of 99.15 billion yuan, down 3.9% year-on-year [4][13]. - The industry also saw a decline in non-recurring net profit, which fell by 13.2% year-on-year to 82.67 billion yuan [4]. Sub-sector Performance - **Chemical Preparations**: Revenue decreased by 3.2% to 271.41 billion yuan, and net profit fell by 7.5% to 25.72 billion yuan in H1 2025 [23][30]. - **Traditional Chinese Medicine**: Revenue dropped by 5.5% to 178.60 billion yuan, with net profit slightly down by 0.1% to 22.34 billion yuan [32][37]. - **Biological Products**: Revenue fell by 17.6% to 55.80 billion yuan, and net profit decreased by 31.3% to 6.36 billion yuan [40][45]. - **Pharmaceutical Commerce**: Revenue was 514.18 billion yuan, a slight decline of 0.2%, while net profit increased by 7.2% to 12.04 billion yuan [49][52]. Investment Strategy - The report recommends focusing on innovative drugs and medical devices, with specific companies highlighted for potential investment, including Heng Rui Medicine, Bei Da Pharmaceutical, and Mindray Medical [4].

Core Insights - Tong Ren Tang reported a slight increase in revenue for the first half of 2025, reaching 9.769 billion yuan, but a decline in net profit by 7.39% to 945 million yuan, continuing the trend of 2024 where net profit also decreased [2][3] - The decline in performance over the past two years is attributed to increased industry competition and high raw material costs, particularly the price of natural cow bile, which peaked at 1.7 million yuan per kilogram in December 2024 [3][4] - The company has initiated a management overhaul, with several high-level executives leaving and new appointments being made, which may impact the company's strategic direction and operational efficiency [5][8] Financial Performance - For the first half of 2025, revenue was 9.769 billion yuan, a year-on-year increase of 0.06%, while net profit was 945 million yuan, a decrease of 7.39% [2] - In 2024, the company achieved revenue of 18.597 billion yuan, a 4.12% increase, but net profit fell by 8.54%, marking the first decline in five years [2] - The revenue growth rates for 2024 and the first half of 2025 were significantly lower compared to previous years, with 2021 and 2023 showing growth rates of 22.58% and 30.02% respectively [2] Raw Material Costs - The price of natural cow bile, a key ingredient in Tong Ren Tang's products, saw a dramatic increase of 198.25% from 570,000 yuan per kilogram in early 2023 to 1.7 million yuan per kilogram by the end of 2024 [4] - The introduction of policies allowing the import of cow bile has helped alleviate raw material shortages for pharmaceutical companies [4] Management Changes - A significant management reshuffle occurred, with multiple executives leaving their positions due to "work adjustments," including the general manager and chief accountant [5][8] - New appointments include Chen Jiafu and Pan Baoxia, who were elected as non-independent directors, indicating a shift in governance [6][8] Industry Context - The pharmaceutical industry is facing challenges such as rising raw material costs and intensified competition, which are impacting profitability [3][9] - The integration of Tianjin Tong Ren Tang, in which Beijing Tong Ren Tang Group acquired a 60% stake, presents both opportunities and challenges for the company [9]

Core Viewpoint - 九州通医药集团 reported a steady growth in revenue and net profit for the first half of 2025, driven by its focus on core business and asset securitization strategies [2][3]. Financial Performance - In the first half of 2025, 九州通 achieved a revenue of 811.06 billion yuan, representing a year-on-year increase of 5.10% [2]. - The net profit attributable to shareholders was 14.46 billion yuan, reflecting a growth of 19.70% compared to the previous year [2]. - The net cash flow from operating activities increased by 3.8 billion yuan, attributed to enhanced collection of accounts receivable [2]. Business Growth Drivers - The growth in revenue was supported by a 6.04% increase in the core pharmaceutical distribution business, alongside rapid growth in emerging sectors such as pharmaceutical manufacturing and digital logistics, which saw increases of 10.77% and 24.66% respectively [3][5]. - The successful issuance of public REITs in pharmaceutical warehousing logistics contributed an additional 4.38 billion yuan to net profit [3]. Industry Position - 九州通 is recognized as the largest private pharmaceutical commercial enterprise in China and ranked 165th in the 2025 Fortune "China 500" list [4]. - The company has been acknowledged for its logistics capabilities, being the first in the industry to receive a 5A rating and recognized as a national model for intelligent warehousing logistics [4]. Strategic Initiatives - The company is implementing a "Three New and Two Transformation" strategy, focusing on new products, new retail, new healthcare, digitalization, and real estate securitization [1]. - The new retail strategy has led to the establishment of over 31,535 stores under the "Good Medicine Master" franchise, with a sales increase of 41.30% in the first half of 2025 [8][9]. Digital Transformation - 九州通 has made significant investments in digitalization, with a focus on AI applications, achieving a leading position in the industry [21][23]. - The company has developed various AI-driven solutions to enhance operational efficiency across different business segments [23]. REITs and Asset Management - 九州通's public REIT, launched in February 2025, raised 1.158 billion yuan and was recognized for its high subscription rate, marking a significant milestone in the pharmaceutical logistics sector [24][25]. Talent and ESG Initiatives - The company has prioritized talent acquisition, bringing in 87 key talents in the first half of 2025, and has invested significantly in ESG initiatives, receiving high ratings from various ESG assessment agencies [26][27].

Group 1 - The company has received a total compensation amount of 56,089,816.67 yuan for the expropriation of three properties located in Huangpu District, Shanghai [2][3] - The properties were previously managed by the company and primarily used for rental operations [2][4] - The compensation agreement has been fully executed, and the company will account for the compensation in its current financial results, which is expected to have a positive impact on the annual operating performance [4] Group 2 - The expropriation will not have a significant impact on the company's business operations [4] - The compensation will be processed according to relevant accounting regulations and will be included in the current profit and loss [4]

Core Viewpoint - China Medical announced plans to hold a half-year performance briefing on September 11, 2025, from 15:00 to 16:00 [2] Company Summary - The company is scheduled to conduct its 2025 half-year performance briefing [2]

Core Viewpoint - 九州通医药集团 reported a robust performance in the first half of 2025, achieving growth in both revenue and net profit despite industry challenges, driven by strategic initiatives in new products, new retail, new medical services, digitalization, and real estate securitization [1][2][3] Financial Performance - In the first half of 2025, 九州通 achieved a net profit of 1.446 billion yuan, representing a year-on-year increase of 19.70% [2] - The company's operating revenue grew by 5.10%, with a focus on core business development and asset securitization [2] - The net cash flow from operating activities increased by 380 million yuan compared to the same period last year [2] Business Segments - The core pharmaceutical distribution business generated sales revenue of 67.634 billion yuan, up 6.04% year-on-year [4] - The pharmaceutical manufacturing and digital logistics segments saw revenue growth of 10.77% and 24.66%, respectively [2][4] - The new retail business, including the "好药师" franchise, achieved sales revenue of 14.93 billion yuan, with a total of 31,535 stores by mid-2025 [6] Strategic Initiatives - 九州通's "三新两化" strategy focuses on new products, new retail, new medical services, digitalization, and real estate securitization [1][2] - The company launched a new product strategy that includes a 500 million yuan investment fund aimed at innovative and high-end generic drugs [5] - The digital transformation efforts have positioned 九州通 as a leader in the industry, with significant investments in AI and digital platforms [17][19] Market Position - 九州通 is recognized as the largest private pharmaceutical enterprise in China and ranked 165th in the 2025 Fortune "China 500" list [3] - The company has been acknowledged for its logistics capabilities, being the first in the industry to receive a 5A logistics enterprise rating [3] REITs and Financial Instruments - 九州通 successfully launched its public REIT, raising 1.158 billion yuan, marking a significant milestone in the pharmaceutical logistics sector [20] - The Pre-REITs project has also been initiated, with a total of 16.45 billion yuan raised for pharmaceutical logistics assets [21] Talent and ESG Initiatives - The company has invested 55.2 million yuan in talent acquisition, focusing on strategic roles to enhance competitiveness [22] - 九州通 is actively engaged in ESG initiatives, contributing over 11.37 million yuan to various social causes and achieving high ratings in ESG assessments [22]